Mesoblast has completed enrollment in its 300-patient, sham-controlled Phase 3 trial (MSB-DR004) of rexlemestrocel-L for chronic low back pain due to degenerative disc disease, setting up a 12‑month primary endpoint readout on pain reduction in mid-2027 and a planned BLA submission in Q3 2027 under RMAT, with eligibility for priority review.
The pivotal study randomizes patients to a single intra-discal injection of the allogeneic stromal cell therapy, delivered with hyaluronic acid, versus sham control, with follow-up through 12 months for the primary endpoint and additional assessments of function, quality of life, and opioid cessation. The protocol is intended to confirm signals reported from Mesoblast’s earlier Phase 3 program, which suggested durable reductions in pain and opioid use extending up to three years after a single injection. A particular emphasis in the new trial is the subgroup on prescription opioids, in light of discogenic pain’s disproportionate contribution to opioid utilization.
Strategically, this is a bid to position a one-time, potentially disease-modifying cellular intervention against a field crowded with procedural pain management options and incremental device upgrades. Mesoblast’s choice to anchor the approvable claim on 12‑month pain reduction reflects a negotiated regulatory path and the practical need for a clean, clinically relevant readout. The tension is familiar: chronic back pain studies are prone to large placebo effects and high variability, and prior intradiscal biologic efforts have yielded uneven results when put under sham control. To persuade both regulators and payers, Mesoblast will likely need a compelling signal not only on the primary endpoint but also on functional outcomes and sustained opioid discontinuation, along with a tolerable safety profile free of procedure-related complications.
For research sites, the operational lift is meaningful but contained. Sites will need interventional spine capabilities and chain-of-identity/temperature-controlled handling for a cryopreserved, off‑the‑shelf cell product, plus standardized procedural training for intra-discal administration. Twelve months of follow-up in a pain population raises familiar retention challenges; consistent eDiary capture, opioid tapering protocols, and close safety surveillance will be critical to data integrity. CROs should anticipate intensive monitoring around concomitant medications and rescue therapies, and robust adjudication of opioid use endpoints. Regulators have already afforded RMAT, which reduces timing friction, but CMC scrutiny for allogeneic cell therapies—potency assays, lot consistency, and comparability—remains a gating factor to any filing. On the market access side, coverage decisions will hinge on magnitude and durability of benefit, evidence of reduced downstream procedures, and clarity on site economics and coding for an intradiscal biologic.
Looking ahead, the analysis plan will matter as much as the headline. Watch for prespecified responder definitions tied to MCIDs for both pain and function, handling of multiplicity across key secondaries, and subgroup performance, including the less‑than‑five‑year disease duration cohort that could constrain generalizability. Safety will be closely scrutinized for discitis, radiculopathy, and accelerated degeneration. Manufacturing readiness and release criteria will need to be de‑risked well ahead of the planned BLA timeline to avoid RMAT-enabled reviews stalling on CMC issues. Competitive pressure is intensifying from nonbiologic interventional approaches that promise durable relief with established procedural workflows; rexlemestrocel‑L will need to demonstrate not just non-opioid positioning but operational and economic fit for spine practices. If MSB‑DR004 delivers a clear, durable, and functionally meaningful effect with supportive opioid data, the program could reset expectations for biologics in discogenic pain. If the effect is modest or inconsistent across endpoints, RMAT will not bridge the evidentiary gap to broad adoption.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
